Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020

rates of bleeding, especially intracranial haemorrhage. The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the

  • 0 views
  • 29 Jan, 2021
  • 2 locations
Sub-Clinical Atrial Fibrillation Biomarker Study

This is a sub-study of the ARTESiA study registered as NCT01938248. This study is designed to validate biomarkers in subclinical atrial fibrillation and to determine if the prospective biomarker will be informative of the potential efficacy of treatment.

  • 8 views
  • 24 Jan, 2021
  • 1 location
A Multi-center Study of Apixaban(APPROACH)

The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid

  • 0 views
  • 25 Jan, 2021
  • 1 location
Specific PoC Testing of Coagulation in Patients Treated With DOAC 1

The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban

  • 0 views
  • 27 Jan, 2021
  • 1 location
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants

(include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin K antagonist. With lack of predicted biomarkers

  • 7 views
  • 28 Jan, 2021
  • 21 locations
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling

The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor

  • 0 views
  • 22 Jan, 2021
  • 1 location
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)

MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective

rivaroxaban
edoxaban
thromboembolism
anticoagulants
apixaban
  • 2 views
  • 24 Jan, 2021
  • 1 location
Non-Interventional Study on Effectiveness of Elxaban Tab. in Patients With Non-valvular Atrial Fibrillation

apixaban) who visit hospital. The purpose is to analyze bleeding (major bleeding, minor bleeding), stroke, systemic embolism, death, other clinical events (acute myocardial infarction, pulmonary embolism

embolism
apixaban
fibrillation
stroke
transient ischemic attack
  • 3 views
  • 23 Jan, 2021
  • 1 location
Atrial Fibrillation Research Database

All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in

rivaroxaban
edoxaban
dabigatran
phenprocoumon
vitamin k
  • 2 views
  • 24 Jan, 2021
  • 2 locations
Registry of Patients Prescribed Anticoagulation

" agents: warfarin and heparinoids and the newer direct oral anticoagulants (DOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban.

  • 17 views
  • 25 Jan, 2021
  • 1 location